



#9

PTO/SB/08A (04-03)  
Approved for use through 04/30/2003. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/856,391	
		Filing Date	January 7, 2002	
		First Named Inventor	Marth, Jamey D., et. al.	
		Art Unit	1614-1635	
		Examiner Name	Not yet assigned	
Page	1	of	Attorney Docket Number	19452A-000320US

RECEIVED  
JUN 28 2003  
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
J3	AA	WO	97/06176	A2	02-20-1997			<input type="checkbox"/>
	AB	CA	2186987	A1	04-02-1998			<input type="checkbox"/>
NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T <sup>2</sup>
J3	AC	Maaheimo et al., "Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion evidence that multivalency enhances the saccharide binding to L-section", <i>Eur. J. Biochem.</i> 234: 616-625 (1995).						
	AD	Jain et al., "Inhibition of L- and P-selection by a rationally synthesized novel core 2-like branched structure containing GalNAc-Lewis <sup>x</sup> and Neu5Acα2-3Galβ1-3GalNAc", <i>Glycobiology</i> 8:7: 707-717 (1998).						
	AE	Hindsgaul et al., "Evaluation of Deoxygenated Oligosaccharide Acceptor Analogs as Specific Inhibitors of Glycosyltransferases", <i>The Journal of Biological Chemistry</i> 266:27: 17858-17862 (1991).						
	AF	Ellies et al., "Core 2 Oligosaccharide Biosynthesis Distinguishes between Selection Ligands Essential for Leukocyte Homing and Inflammation", <i>Immunity</i> 9: 881-890 (1998).						

Examiner Signature		Date Considered	5/20/04
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.